Horizon Therapeutics (HZNP) PT Raised to $118 at BMO Capital

February 24, 2021 5:34 PM EST Send to a Friend
BMO Capital analyst Gary Nachman raised the price target on Horizon Therapeutics (NASDAQ: HZNP) to $118.00 (from $115.00) while maintaining ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login